"We believe that the potential for a simple anti-viral treatment for patients that can be initiated immediately upon diagnosis will be important - especially for those patients with the greatest need, such as the elderly and immunocompromised who often take other medicines for their medical conditions that may be incompatible with drugs like ritonavir." Assuming data from our Phase 1 clinical study continues to support advancement of PBI-0451, we plan to evaluate our tablet formulation in Q1 2022 and - pending regulatory approval - to initiate a Phase 2/3 registrational study in mid 2022," continued Dr. "As we dose escalate, the tolerability and pharmacokinetics to date continue to support the potential for dosing of PBI-0451 as a single agent, without the use of a second ‘boosting’ agent to help increase its levels in the body such as ritonavir, which is used in conjunction with Pfizer’s protease inhibitor (PAXLOVID™). The Pardes team believes that oral protease inhibitors are potentially easier to make, transport, and administer than injectable treatments such as antibodies and vaccines, so their manufacture and distribution to patients may face fewer barriers. This class of drugs has the potential, if taken upon exposure or as treatment when symptoms arise, to lower the risk of hospitalization and death, particularly among individuals who are at higher risk for severe infection, such as those with other medical conditions who are vaccinated but with a poor or diminished immune response or are unvaccinated. ("Pfizer") has helped to demonstrate the potential of their protease inhibitor (when used together with a second drug called ritonavir) to be a potentially important new tool to address the COVID-19 pandemic. This class of drug has been successfully deployed against diseases such as HIV and hepatitis C. PBI-0451 is a type of antiviral drug called a protease inhibitor.
"At Pardes, our aspiration is to be a leader in the development of potential therapies against these types of viruses, starting with PBI-0451 which is in Phase I clinical studies." This eventuality appears more likely with the spread of new highly transmissible variants, such as Delta and Omicron," said Uri Lopatin, M.D., Chief Executive Officer of Pardes Biosciences. "We believe that direct-acting antivirals against coronavirus that are taken orally – such as our PBI-0451 – will become increasingly important in a world where SARS-CoV-2 may become endemic. ("Pardes"), the CEOs of both companies are sharing their thoughts on the COVID-19 public health emergency and how they expect the combined company to play an important role in addressing one of the biggest health crises of our time. II (NASDAQ: FSII) and Pardes Biosciences, Inc. SAN FRANCISCO & LARKSPUR, Calif., December 21, 2021-( BUSINESS WIRE)-In advance of the shareholder vote for the business combination between FS Development Corp.
Pardes biosciences trial#
Proposed merger heads to shareholder vote on December 23 rd as ongoing Phase I trial shows potential for unboosted oral regimen
0 kommentar(er)
